DRIVE trial; remote education and medication program; T2D

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
ACC.24
Beneficial effects of GLP-1RA in patients with obesity-related HFpEF and T2D
- Mikhail Kosiborod, MD
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
ACC.24
Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
- Alexander Fanaroff, MD
Promising results for self-expanding TAVR device in trial with mostly women
Promising results for self-expanding TAVR device in trial with mostly women
ACC.24
Promising results for self-expanding TAVR device in trial with mostly women
- Hadley Wilson, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD

Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk